Survival Disparities of Diffuse Large B-Cell Lymphoma (DLBCL) in a Community-Based Inner-City Cancer Center

Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Andrew Tiu, Vinicius Jorge, Peter Moussa, Djeneba Audrey Djibo, Sorab Gupta, Onder Alpdogan, Claudia Dourado
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Cancer treatment, particularly that of multiple myeloma (MM), has drastically evolved over the past decade as we better understood the tumor microenvironment and began utilizing therapies to target tumor cells1,2. This has been accomplished with monoclonal and bispecific antibodies as well as chimeric antigen receptor (CAR)-T cell therapy3-5. However, management of patients who have failed approved agents and have rapidly progressive disease with cytopenias continues to be challenging. Many patients hope to qualify for a clinical trial option, particularly when their disease becomes triple-class or penta-refractory with a ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
This study examined distress and quality of life in indolent NHL/CLL patients in active surveillance or cancer-directed treatment over the first-year post-diagnosis.PATIENTS AND METHODS: Adult patients (≥21 years) with newly diagnosed indolent NHL/CLL completed electronic self-report measure of distress and quality of life every 4 months over the course of a year for a total of 4 surveys. Fisher's exact test and t-tests were used to examine demographic and disease differences between patients receiving different treatments. Mixed-effect models were also used to compare overall differences between treatment status over t...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
THERE are myriad symptoms to look out for when detecting the early stages of blood cancer. These indications differ when determining the nature of blood cancer, whether it is lymphoma, leukaemia myeloma, MDS, MPN or any other classification. However, recent studies have discovered an emerging symptom to look out for during the night.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Clin Lymphoma Myeloma Leuk. 2021 Aug 4:S2152-2650(21)00305-0. doi: 10.1016/j.clml.2021.07.023. Online ahead of print.ABSTRACTBACKGROUND: Whether the characteristics and outcome of secondary acute promyelocytic leukemia (s-APL) are similar to de no APL (dn-APL) remains unknown.PATIENTS AND METHODS: Using the SEER database, we identified 3877 patients with APL diagnosed from 2000 to 2014, including 465 s-APL and 3412 dn-APL.RESULTS: Compared with dn-APL, s-APL werecharacterized by older median age, and a higher early mortality rate. Multivariate Cox model showed s-APL, older age, earlier year of diagnosis, and male gender we...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
Tumor necrosis factor alpha (TNF- α) is a cytokine with a key role in proinflammation and multiple diseases, including cancer. The gene encoding TNF-α is located within a highly polymorphic region on chromosome 6p21.3; two polymorphisms -308G/A (rs1800629) and -238G/A (rs361525) have been associated with occurrence of human diseas es. There is a debate in recent meta-analyses that reached discrepant conclusions regarding the potential role of TNF-α polymorphisms in multiple myeloma (MM) risk. The aim of this systematic review and meta-analysis is to investigate the association between the aforementioned t...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
CONCLUSION: Survey respondents described their role in treatment decision making for newly diagnosed HL. Nearly half of patients did not endorse participating in shared decision making. A substantial number had experienced LEs. Future work should focus on improving patient-provider communication in decision processes for newly diagnosed HL.PMID:34452864 | DOI:10.1016/j.clml.2021.07.034
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-cell Marginal Zone;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   B-cell Lymphoma;   Waldenstrom Macroglobulinemia;   Lymphoma, Mantle-Cell Interventions:   Drug: LOXO-338;   Drug: Pirtobrutinib Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Leukemia | Lymphoma | Myeloma